NEWS
Switch Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference
Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics, will participate in a virtual fireside chat at the Evercore ISI 2024 Emerging Biotech Conference…
Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer
Veteran RNA expert, oligonucleotide chemist and biotech industry expert, Charles Allerson, Ph.D., joins Switch Therapeutics from DTx Pharma to lead the acceleration of the Company’s novel CASi platform —
Switch Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
Dee Data, Ph.D., Co-Founder and CEO of Switch Therapeutics, will present a corporate overview at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023.
Switch Therapeutics Appoints Douglas Fambrough, Ph.D., to Board of Directors
Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, today announced the appointment of Douglas Fambrough, Ph.D., as an independent director to its Board.
Switch Therapeutics Announces Formation of Scientific Advisory Board
Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, today announced its Scientific Advisory Board made up of Drs. Marc Abrams, David Bredt and James Treanor.
Switch Therapeutics Expands Leadership Team with Key Appointments
Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use RNA science to treat diseases, today announced the appointments of Craig Blanchette, Ph.D., as Senior Vice President, Research and Michael Wolfe as Senior Vice President, Finance and Operations, effective immediately.